ACTRN12605000514606进行中（未招募）不适用
EPISODE II: Prevention of relapse following early psychosis using combined family and individual CBT
Eli Lily0 个研究点目标入组 120 人开始时间: 2005年9月26日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Prevention
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 15 Years 至 25 Years（—）
- 性别
- All
入选标准
- •(1) Eligible for EPPIC services (DSM-IV diagnosis of a psychotic disorder or mood disorder with psychotic features, no more than 6 months of prior treatment with an antipsychotic prior to registration with EPPIC) and Barwon Heath First Episode Psychosis Service (see EPPIC criteria above), with a maximum of 12 months of treatment received within the service; (2) Able to converse in English without an interpreter; and (3) Have reached complete, or near-complete remission of positive psychotic sypmtoms for a 1-month period, determined by scores on the expanded BPRS (Overall & Gorham, 1962) of 3 or less on the items hallucinations, conceptual disorganization, suspiciousness and unusual thought content.
排除标准
- •(1) Unable to converse in, or read English without an interpreter; (2)Severe intellectual disability; (3)Persistent positive psychotic symptoms; and (4) Psychotic disorder due to a medical condition.
研究者
相似试验
已完成
不适用
The study on the prevention of recurrence of early gastric cancer after endoscopic therapyGastric cancerJPRN-UMIN000009360Gastroenterology Division, Yokohama City University Hospital300
尚未招募
3 期
Does Escitalopram helps in early recovery and prevent relapse in cases of idiopathic central serous retinopathy which causes blister like elevation at the centre of retina causing loss of visioCTRI/2011/11/002148DrGNageswar Rao110
进行中（未招募）
1 期
Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax™ Treatment (PRESENT)EUCTR2011-005219-98-HUGalena Biopharma, Inc700
进行中（未招募）
1 期
Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax™ Treatment (PRESENT)Operable early-stage, node-positive breast cancerMedDRA version: 19.0Level: LLTClassification code 10071113Term: Node-positive breast cancerSystem Organ Class: 100000004864EUCTR2011-005219-98-BGGalena Biopharma, Inc709
进行中（未招募）
1 期
Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax™ Treatment (PRESENT)Operable early-stage, node-positive breast cancerMedDRA version: 18.1Level: LLTClassification code 10071113Term: Node-positive breast cancerSystem Organ Class: 100000004864EUCTR2011-005219-98-GBGalena Biopharma, Inc709